Cigna Corporation
NYSE:CIMedical - Healthcare Plans
-$4.44 today
- Market cap
- $75.20B
- Beta
- 0.30
- P/E (TTM)
- 11.7
- EPS (TTM)
- $23.95
- Dividend yield
- 2.19%
Volume 2.49M
Average 1.61M
CI EBITDA Margin
EBITDA as a percentage of revenue.
Cigna CorporationNYSE: CI
EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026
EBITDA Margin holds steady near 4.5%
EBITDA Margin was 4.5% in Q3 FY2026, down 0.3 pp from a year earlier. On a trailing-twelve-month basis it was 4.4%, down 0.2 pp year over year. Over 3 fiscal years it narrowed by 2.1 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 12 analysts of 5.0% for the fiscal year ending Dec 2026, up from 4.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 4.5%-0.1 pp QoQ
- Last fiscal yearDec 2025
- 4.3%-0.8 pp YoY
- LTMSep 2026
- 4.4%-0.2 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.3 pp | +1.1 pp | +1.4 pp |
| 1 year | -0.8 pp | +0.7 pp | +1.5 pp |
| 3 years | -2.1 pp | +0.6 pp | +2.7 pp |
| 5 years | +1.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 4.3%
- Year-over-year change
- -0.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.3% | -0.8pp |
| FY2024 | 2024-12-31 | 5.0% | -1.1pp |
| FY2023 | 2023-12-31 | 6.2% | -0.2pp |
| FY2022 | 2022-12-31 | 6.4% | +0.0pp |
| FY2021 | 2021-12-31 | 6.4% | — |
EBITDA Margin vs competitors
How CI compares with its peers on the latest reported figures
- CI's LTM Sep 2026 EBITDA Margin of 4.4% is the 3rd highest of the 9 companies compared; the peer median is 2.7%.
- Its year-over-year change of -0.2 pp is the 3rd highest of 9, against a peer median of -0.6 pp.
- Over three fiscal years its change of -2.1 pp compares with a peer median of -1.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 6.2% | -0.8 pp | -4.7 pp | |
| LTM Sep 2026 | 4.4% | -0.7 pp | -1.6 pp | |
| LTM Sep 2026 | 4.4% | -0.2 pp | -2.1 pp | |
| LTM Jun 2026 | 4.1% | +5.0 pp | +10.5 pp | |
| LTM Jun 2026 | 3.2% | -0.4 pp | -1.4 pp | |
| LTM Sep 2026 | 2.1% | -0.4 pp | -2.9 pp | |
| LTM Mar 2026 | 1.6% | +2.9 pp | +9.1 pp | |
| LTM Sep 2026 | 0.8% | -2.7 pp | -2.1 pp | |
| LTM Jun 2026 | -1.4% | -4.0 pp | -5.5 pp | |
| Peer median (excluding CI) | 2.7% | -0.6 pp | -1.8 pp | |
Competitors are the stored peer set for CI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 174.07B | 180.52B | 195.27B | 247.12B | 274.95B |
| Cost of Revenue | 151.12B | 157.02B | 170.09B | 221.16B | 248.97B |
| Gross Profit | 22.95B | 23.5B | 25.18B | 25.96B | 25.99B |
| Gross Margin | 13.2% | 13.0% | 12.9% | 10.5% | 9.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 12.79B | 13.05B | 14.32B | 14.57B | 14B |
| Operating Expenses | 15.01B | 15.05B | 16.64B | 16.55B | 16.86B |
| Depreciation & Amortization | 2.92B | 2.94B | 3.04B | 2.78B | 2.78B |
| EBITDA | 11.09B | 11.52B | 12.07B | 12.47B | 11.75B |
| EBITDA Margin | 6.4% | 6.4% | 6.2% | 5.0% | 4.3% |
| Operating Income | 7.94B | 8.45B | 8.54B | 9.42B | 9.13B |
| Operating Margin | 4.6% | 4.7% | 4.4% | 3.8% | 3.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.21B | 1.23B | 1.45B | 1.44B | 1.38B |
| Other Income / Expenses | (1.15B) | (53M) | (3.02B) | (4.15B) | (1.54B) |
| Income Before Tax | 6.79B | 8.4B | 5.51B | 5.27B | 7.59B |
| Pre-Tax Margin | 3.9% | 4.7% | 2.8% | 2.1% | 2.8% |
| Income Tax Expense | 1.37B | 1.62B | 141M | 1.49B | 1.35B |
| Net Income | 5.37B | 6.7B | 5.16B | 3.43B | 5.96B |
| Net Margin | 3.1% | 3.7% | 2.6% | 1.4% | 2.2% |
| EPS (Basic) | 15.89 | 21.66 | 17.57 | 12.25 | 22.30 |
| EPS (Diluted) | 15.75 | 21.41 | 17.39 | 12.12 | 22.17 |
| Weighted Avg Shares | 337.96M | 313.07M | 296.88M | 280.29M | 265.95M |
| Weighted Avg Shares (Diluted) | 340.97M | 313.07M | 296.88M | 283.22M | 265.95M |
Cigna Corporation
NYSE:CI
Intrinsic Alpha fair value
Locked
Current Price
$285.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.